Silence Therapeutics: Divesiran Targets High-Burden PV [Seeking Alpha]
Silence Therapeutics Plc - American Depository Share (SLN)
Company Research
Source: Seeking Alpha
SLN boasts a strong cash position ($100M+), providing runway through 2028 and enabling continued pipeline development without near-term financing risks. The SANRECO trial's design and patient population position divesiran as a potential adjunctive therapy for high-burden PV patients, focusing on reduced phlebotomy frequency and infrequent dosing. While acknowledging clinical and market risks, I maintain a cautiously optimistic outlook, seeing significant upside if Phase 2 data demonstrate efficacy and safety. quantic69/iStock via Getty Images I think Silence Therapeutics ( SLN ) is currently at an interesting stage. I see it as a focused, clinical-stage RNAi-focused drug development company, but its valuation continues to reflect historical execution concerns and general small-cap biotech exhaustion more so This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate
Show less
Read more
Impact Snapshot
Event Time:
SLN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SLN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SLN alerts
High impacting Silence Therapeutics Plc - American Depository Share news events
Weekly update
A roundup of the hottest topics
SLN
News
- Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceBusiness Wire
- Need To Know: Analysts Just Made A Substantial Cut To Their Silence Therapeutics plc (NASDAQ:SLN) Estimates [Yahoo! Finance]Yahoo! Finance
- Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire
- Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)Business Wire
- Silence Therapeutics (NASDAQ:SLN) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
SLN
Analyst Actions
- 9/16/25 - HC Wainwright
SLN
Sec Filings
- 11/14/25 - Form 4
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form 10-Q
- SLN's page on the SEC website